Effectiveness and safety of antiplatelet therapy in stroke recurrence prevention in patients with liver cirrhosis: a 2‐year follow‐up study
- 19 October 2012
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 21 (12) , 1334-1343
Abstract
Background: Data are limited on antiplatelet therapy for ischemic stroke prevention in liver cirrhosis patients.Methods: This retrospective study identified cases of liver cirrhosis from the National Health Insurance Research Database. Antiplatelet therapy was administered for 2 years to patients who had experienced a first ischemic stroke between 1997 and 2006. Primary outcomes, including death and readmission to hospital for stroke, and secondary outcomes, including death, stroke, or gastrointestinal bleeding, were examined.Results: One thousand one hundred eighty patients experienced a first stroke. According to time‐dependent analysis, the hazard ratio for primary outcomes in patients treated with aspirin was 0.915 (95%CI: 0.872–0.960). In secondary outcomes, hazard ratio for readmission for stroke was 0.904 (95%CI: 0.836–0.978) and that for gastrointestinal bleeding was 0.998 (95%CI: 0.946–1.052) in patients treated with aspirin. Subgroup analysis showed that aspirin was more effective in patients with non‐alcoholic cirrhosis than in those with other types of liver cirrhosis. Moreover, hyperlipidemia and statins may have decreased the efficacy of antiplatelet therapy in cirrhosis patients.Conclusions: This study includes the largest sample for evaluating outcomes of antiplatelet therapy in liver cirrhosis patients for preventing recurrent stroke. The study results show that antiplatelet therapy still offers safe and effective treatment for ischemic stroke prevention in patients with cirrhosis. Copyright © 2012 John Wiley & Sons, Ltd.Keywords
Funding Information
- National Science Council (NSC100-2320-B-037-017)
This publication has 24 references indexed in Scilit:
- Coronary Artery Stents and Antiplatelet Therapy in Patients With CirrhosisJournal of Clinical Gastroenterology, 2012
- Secondary preventive medication persistence and adherence 1 year after strokeNeurology, 2011
- Liver Cirrhosis and Risk of Intracerebral HemorrhageStroke, 2011
- Platelet count for predicting fibrosis in nonalcoholic fatty liver diseaseJournal of Gastroenterology, 2011
- Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatmentAtherosclerosis, 2010
- Statins in Primary Biliary Cirrhosis: Are They Safe?Digestive Diseases and Sciences, 2009
- Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver diseaseGut, 2008
- The Beneficial Effect of Aspirin and Enoxaparin on Fibrosis Progression and Regenerative Activity in a Rat Model of CirrhosisDigestive Diseases and Sciences, 2007
- Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromesCancer, 2006
- Reduced prevalence of ischemic events and abnormal supraortic flow patterns in patients with liver cirrhosisLiver International, 2005